Phase II Study of Nimotuzumab (TheraCim-hR3) Concurrent With Cisplatin/Radiotherapy in Patients With Locally Advanced Head and Neck Squamous Cell Carcinoma (HNSCC).

Trial Profile

Phase II Study of Nimotuzumab (TheraCim-hR3) Concurrent With Cisplatin/Radiotherapy in Patients With Locally Advanced Head and Neck Squamous Cell Carcinoma (HNSCC).

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 03 May 2018

At a glance

  • Drugs Nimotuzumab (Primary) ; Cisplatin
  • Indications Head and neck cancer; Squamous cell cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 25 Apr 2018 Planned End Date changed from 1 Mar 2018 to 1 Mar 2019.
    • 25 Apr 2018 Planned primary completion date changed from 1 Mar 2018 to 1 Mar 2019.
    • 21 Dec 2017 Planned End Date changed from 1 Dec 2017 to 1 Mar 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top